Close Menu

NEW YORK – Elios Therapeutics reported positive top-line results from a Phase IIb study involving its personalized vaccine in patients with advanced, resected melanoma. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.